Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
With billions of dollars at stake in potential legal liabilities, the life sciences giant is exploring a possible solution – bankruptcy of a sort.
On Friday, the agency approved belumosudil as a new treatment option for anyone over 12 with cGVHD after two prior lines of therapy have failed.
The CDC Advisory Committee on Immunization Practices is planning a meeting in October to recommend the vaccine’s use in adults.
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
Regeneron continues to expand its presence in New York. Over the next six years, the company will invest approximately $1.8 billion to expand its Tarrytown facilities. The investment will support the addition of 1,000 new jobs.
Biotech jobs are one of the most promising career paths for people who are into life sciences and those who dream of creating change in the world through developing breakthrough medicines and therapeutics.
The coronavirus disease (COVID-19) pandemic that has ravaged across the globe has demanded more experts in microbiology, particularly jobs in virology.
Addressing employee burnout signs at an early stage will help build a healthy relationship. It can also help improve the performance. Let’s look at some other benefits.
There are two PDUFA dates on the U.S. Food and Drug Administration’s calendar for this week. Here’s a look.
Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
In 2016, Mylan’s EpiPen became the flashpoint of drug pricing outrage when it became widely reported the life-saving drug had increased more than 400% in price over a period of seven years.
It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
PRESS RELEASES
· Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients · Strengthening MIC-Lx’s regulatory and commercial positioning in Europe
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections